Abbott India Limited
NSE: ABBOTINDIA BSE: ABBOTINDIA
Prev Close
30710
Open Price
30755
Volume
4,806
Today Low / High
30580 / 30975
52 WK Low / High
25200 / 31898.95
Range
29,156 - 32,225
Prev Close
30715.8
Open Price
30000.4
Volume
276
Today Low / High
30000.4 / 30931.7
52 WK Low / High
25200.05 / 31900
Range
29,148 - 32,216
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 30690 (target range: 29,156 - 32,225), reflecting a change of -20 (-0.06512537%). On the BSE, it is listed at 30681.95 (target range: 29,148 - 32,216), showing a change of -33.85 (-0.1102%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Abbott India Limited Graph
Abbott India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Abbott India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 30,690.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 30,681.95 | 30,988.77 | 27,889.89 - 34,087.65 |
| 31,295.59 | 25,036.47 - 37,554.71 | ||
| 31,602.41 | 22,121.69 - 41,083.13 | ||
| Bearish Scenario | 30,681.95 | 30,375.13 | 27,337.62 - 33,412.64 |
| 30,068.31 | 24,054.65 - 36,081.97 | ||
| 29,761.49 | 20,833.04 - 38,689.94 |
Overview of Abbott India Limited
ISIN
INE358A01014
Industry
Drug Manufacturers - General
Vol.Avg
15,172
Market Cap
652,141,017,000
Last Dividend
410
Official Website
IPO Date
2002-08-12
DCF Diff
-42,311.85
DCF
73,002
Financial Ratios Every Investor Needs
Stock Dividend of ABBOTINDIA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-07-19 | July 19, 24 | 410 | 410 | 2024-07-19 | 2024-09-07 | |
| 2023-07-21 | July 21, 23 | 145 | 145 | 2023-07-21 | 2023-09-08 | |
| 2022-08-02 | August 02, 22 | 130 | 130 | 2022-08-03 | 2022-09-09 | |
| 2021-07-19 | July 19, 21 | 155 | 155 | 2021-07-20 | 2021-08-26 | |
| 2020-08-28 | August 28, 20 | 143 | 143 | 2020-08-31 | 2020-10-07 | 2020-06-08 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 5,847.19 Cr | 3,232.69 Cr | 2,614.50 Cr | 0.4471 | 0.96 Cr | 126.69 Cr | 1,405.54 Cr | 1,201.22 Cr | 565.30 | 1,697.80 Cr | 0.2054 |
| 2023-03-31 | 5,346.73 Cr | 2,986.08 Cr | 2,360.65 Cr | 0.4415 | 0.79 Cr | 131.67 Cr | 1,147.27 Cr | 949.41 Cr | 446.80 | 1,356.03 Cr | 0.1776 |
| 2022-03-31 | 4,910.30 Cr | 2,667.94 Cr | 2,242.36 Cr | 0.4567 | 0.81 Cr | 158.40 Cr | 1,025.92 Cr | 798.70 Cr | 375.87 | 1,161.25 Cr | 0.1627 |
| 2021-03-31 | 4,307.59 Cr | 2,400.28 Cr | 1,907.31 Cr | 0.4428 | 0.84 Cr | 134.22 Cr | 872.22 Cr | 690.69 Cr | 325.04 | 998.26 Cr | 0.1603 |
| 2020-03-31 | 4,091.18 Cr | 2,325.15 Cr | 1,766.03 Cr | 0.4317 | 0.69 Cr | 81.46 Cr | 705.17 Cr | 592.93 Cr | 279.04 | 870.83 Cr | 0.1449 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 291.74 Cr | 5,193.49 Cr | 1,494.60 Cr | 3,698.8900 Cr | 83.23 Cr | -208.51 Cr | 619.58 Cr | 228.39 Cr | 7.40 Cr | 0.00 Cr | -169.73 Cr | 1,342.7200 Cr |
| 2023-03-31 | 239.67 Cr | 4,555.51 Cr | 1,366.97 Cr | 3,188.5400 Cr | 113.17 Cr | -126.50 Cr | 648.85 Cr | 233.05 Cr | 4.71 Cr | 0.00 Cr | -460.66 Cr | 1,206.0200 Cr |
| 2022-03-31 | 132.71 Cr | 4,224.12 Cr | 1,404.33 Cr | 2,819.7900 Cr | 151.69 Cr | 18.98 Cr | 687.82 Cr | 263.03 Cr | 4.07 Cr | 0.00 Cr | -2,575.42 Cr | 1,203.1900 Cr |
| 2021-03-31 | 218.27 Cr | 3,840.45 Cr | 1,238.29 Cr | 2,602.1600 Cr | 152.58 Cr | -65.69 Cr | 717.59 Cr | 250.27 Cr | 0.00 Cr | 0.00 Cr | 46.62 Cr | 1,030.8600 Cr |
| 2020-03-31 | 145.14 Cr | 3,546.85 Cr | 1,115.15 Cr | 2,431.7073 Cr | 174.89 Cr | 29.75 Cr | 527.17 Cr | 270.57 Cr | 0.00 Cr | 0.00 Cr | -2,015.80 Cr | 891.1100 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,212.8100 Cr | -559.6600 Cr | -744.7100 Cr | 1,164.4800 Cr | 52.0700 Cr | 291.7400 Cr | -48.3300 Cr | 1,201.2200 Cr | 0.0000 Cr | -690.6000 Cr | 29.2600 Cr |
| 2023-03-31 | 893.3900 Cr | -147.7100 Cr | -638.7200 Cr | 859.2800 Cr | 106.9600 Cr | 239.6700 Cr | -34.1100 Cr | 1,273.8200 Cr | 0.0000 Cr | -584.3600 Cr | 38.9700 Cr |
| 2022-03-31 | 947.6600 Cr | -395.8400 Cr | -637.3800 Cr | 903.5900 Cr | -85.5600 Cr | 132.7100 Cr | -44.0700 Cr | 1,079.7300 Cr | 0.0000 Cr | -584.3600 Cr | 29.7800 Cr |
| 2021-03-31 | 726.7400 Cr | -71.8200 Cr | -581.7900 Cr | 703.4300 Cr | 73.1300 Cr | 218.2700 Cr | -23.3100 Cr | 925.9500 Cr | 0.0000 Cr | -531.2300 Cr | -190.4200 Cr |
| 2020-03-31 | 626.1091 Cr | -401.2100 Cr | -216.7866 Cr | 610.3900 Cr | 8.1300 Cr | 145.1400 Cr | -15.7400 Cr | 802.6915 Cr | 0.0000 Cr | -166.5116 Cr | 79.6232 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 1,614.28 Cr | 892.70 Cr | 721.58 Cr | 0.4470 | 418.10 Cr | 360.78 Cr | 169.78 | 507.84 Cr | 0.2235 |
| 2024-09-30 | 1,632.67 Cr | 901.76 Cr | 730.91 Cr | 0.4477 | 421.45 Cr | 358.61 Cr | 168.76 | 499.44 Cr | 0.2196 |
| 2024-06-30 | 1,557.61 Cr | 1,025.79 Cr | 531.82 Cr | 0.3414 | 372.64 Cr | 328.01 Cr | 154.36 | 458.34 Cr | 0.2106 |
| 2024-03-31 | 1,438.63 Cr | 969.33 Cr | 469.30 Cr | 0.3262 | 311.34 Cr | 287.06 Cr | 135.09 | 410.68 Cr | 0.1995 |
| 2023-12-31 | 1,437.14 Cr | 776.79 Cr | 660.35 Cr | 0.4595 | 369.72 Cr | 310.98 Cr | 146.34 | 443.30 Cr | 0.2164 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 637.69 Cr | 1,247.99 Cr | 1,885.68 Cr | 0.00 Cr | 739.14 Cr | 3,107.30 Cr | 221.07 Cr | 5,063.02 Cr | 1,541.91 Cr |
| 2024-03-31 | 291.74 Cr | 1,826.25 Cr | 2,117.99 Cr | 460.59 Cr | 619.58 Cr | 3,245.84 Cr | 228.39 Cr | 5,193.49 Cr | 1,494.60 Cr |
| 2023-12-31 | -1,951.55 Cr | 3,903.10 Cr | 1,951.55 Cr | 0.00 Cr | 0.00 Cr | 1,951.55 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 578.13 Cr | 1,373.42 Cr | 1,951.55 Cr | 377.55 Cr | 512.39 Cr | 2,950.71 Cr | 230.78 Cr | 4,515.94 Cr | 1,407.02 Cr |
| 2023-06-30 | -1,922.40 Cr | 3,844.80 Cr | 1,922.40 Cr | 0.00 Cr | 0.00 Cr | 1,922.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 328.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 287.06 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 310.98 Cr | 35.94 Cr | 0.00 Cr | 0.00 Cr | 35.94 Cr | 1,987.49 Cr | 1,951.55 Cr | 0.00 Cr | 35.94 Cr |
| 2023-09-30 | 312.94 Cr | 683.63 Cr | 372.22 Cr | -717.39 Cr | 0.00 Cr | 578.13 Cr | 0.00 Cr | -33.73 Cr | 649.90 Cr |
| 2023-06-30 | 290.24 Cr | 34.34 Cr | 0.00 Cr | 0.00 Cr | 34.34 Cr | 286.75 Cr | 252.41 Cr | 0.00 Cr | 34.34 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,515.20 | ₹1,223,701,278,400.00 | ₹1,211,559.00 |
| Abbott India Limited | ABBOTINDIA | ₹30,690.00 | ₹652,141,017,000.00 | ₹4,806.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,906.80 | ₹492,429,360,800.00 | ₹151,023.00 |
| Gland Pharma Limited | GLAND | ₹1,449.40 | ₹238,797,346,400.00 | ₹140,459.00 |
| Pfizer Limited | PFIZER | ₹4,164.20 | ₹190,502,705,594.00 | ₹17,454.00 |
| Sanofi India Limited | SANOFI | ₹6,221.50 | ₹143,281,145,000.00 | ₹7,422.00 |
| Marksans Pharma Limited | MARKSANS | ₹211.44 | ₹95,816,996,160.00 | ₹609,083.00 |
Key Executives
Gender: male
Year Born:
Gender: female
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
FAQs about Abbott India Limited
The CEO is Ms. Swati Dalal.
The current price is ₹30,690.00.
The range is ₹25200-31898.95.
The market capitalization is ₹65,214.10 crores.
The dividend yield is 1.34%.
The P/E ratio is 48.87.
The company operates in the Healthcare sector.
Overview of Abbott India Limited (ISIN: INE358A01014) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹65,214.10 crores and an average daily volume of 15,172 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹410.